Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro - Scorecard - MDSpire

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • By

  • Yi-Ping Shih

  • Stephan Drokin

  • Olivia Burke

  • Huayu Huang

  • Amy Leung

  • Marco Bravo-Manriquez

  • Myungkyu Jang

  • Marina S. Syrkina

  • Laura Julian

  • Nelson Sanjuan

  • Eric Tran

  • May 15, 2026

  • 0 min

Share

Clinical Scorecard: Rapid Clinical-Scale Manufacturing of TCR-T Cells Over 10 Days Utilizing IL-2/7/15 and TGF-β Enhances Early Memory and Tissue-Resident Phenotypes Alongside Strong Antitumor Efficacy In Vitro

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with solid tumors, specifically those with KRAS G12D mutations.
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Assess TCR-T cell phenotype and functionality post-manufacturing, including specific markers and assays.

      Risks

        Patient & Prescribing Data

        Patients with colorectal cancer and pancreatic ductal adenocarcinoma.

        TCR-T cells produced with the cytokine cocktail demonstrate superior characteristics for ACT.

        Clinical Best Practices

        • additional_info

        Related Resources & Content

        Original Source(s)

        Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

        • by Yi-Ping Shih, Stephan Drokin, Olivia Burke, Huayu Huang, Amy Leung, Marco Bravo-Manriquez, Myungkyu Jang, Marina S. Syrkina, Laura Julian, Nelson Sanjuan, Eric Tran

        • May 15, 2026

        Related Content

        Synthetic short RNA in cancer

        Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

        Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report